The Efficacy of G-CSF Against Adhesion Reformation After Hysteroscopic Adhesiolysis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310018
- Recruiting
- Sir Run Run Shaw Hospital
-
Contact:
- Yamei Xue, Master
- Phone Number: +8657186002222
- Email: yaya7450@sina.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Moderate and severe intrauterine adhesion patients(AFS score ≥5)
- age 18-40
- first time receiving hysteroscopic adhesiolysis
- provided COOK balloon as adjuvant adhesion prevention treatment
- accepting randomized trial
Exclusion Criteria:
- Mild adhesion patients
- uterine shape can't be restored in the end of surgery
- abnormal chromosome phenotype
- systemic disease
- no fertility desire
- contradiction of G-CSF injection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: G-CSF
G-CSF(1.8ml) will be injected into the uterine cavity by insemination catheter 7 days after first hysteroscopic adhesiolysis.
|
7 days after first hysteroscopic adhesiolysis, G-CSF will be injected into the uterine cavity after balloon removing.
Other Names:
In all cases hormone therapy was commenced shortly after the operation, consisting of oestradiol valerate at a dose of 6 mg per day for 21-28 days with the addition of medroxyprogesterone acetate at a dose of 6 mg per day for the last 7-10 days of the oestrogen therapy.
Following the withdrawal bleed, the hormone therapy was repeated for another cycle.
Other Names:
At the end of the procedure, the Cook balloon were placed in the uterine cavity of each patient.the
device was removed after 7 days.
|
|
PLACEBO_COMPARATOR: Normal saline
equal volume of normal saline(1.8ml)
will be injected into the uterine cavity by insemination catheter 7 days after first hysteroscopic adhesiolysis.
|
In all cases hormone therapy was commenced shortly after the operation, consisting of oestradiol valerate at a dose of 6 mg per day for 21-28 days with the addition of medroxyprogesterone acetate at a dose of 6 mg per day for the last 7-10 days of the oestrogen therapy.
Following the withdrawal bleed, the hormone therapy was repeated for another cycle.
Other Names:
At the end of the procedure, the Cook balloon were placed in the uterine cavity of each patient.the
device was removed after 7 days.
7 days after first hysteroscopic adhesiolysis, normal saline will be injected into the uterine cavity after balloon removing.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adhesion reformation rate
Time Frame: 2 months after first surgery
|
Adhesion reformation rate after first adhesiolysis
|
2 months after first surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pregnancy rate
Time Frame: 3 years after first surgery
|
pregnancy rate after adhesiolysis
|
3 years after first surgery
|
|
Live birth rate
Time Frame: 4 years after first surgery
|
live birth rate after adhesiolysis
|
4 years after first surgery
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Endometrial thickness
Time Frame: 1 months after G-CSF injection
|
Endometrial thickness in the ovulation phase after G-CSF injection
|
1 months after G-CSF injection
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SRRSHRMC2016001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.